By using a patented chemotherapeutic galvanostat/potentiostat (CGP) like: The Joey™ from Innovative Potential™, drug molecules work better™ by affording: high-presicion surgical control, expanded reactivity and application options, and increased placement control over pharmaceutical concentration.

​

Work better™ is to have external control over bioactivation and to have improved efficacy versus the precursor compound.

​

Back in 2011 I demonstrated the practical application of electrochemical prodrug activation in the first proof-of-concept for EAC (figure1).

​

​

​

​

​

​

​

​

Figure 1. Cytotoxicity of the electrolysis of nontoxic prodrugs​ into cytotoxic molecules**. Left panel: cyclophosphamide; right panel: acetaminophen. Electrolysis was performed in a divided flow cell at three concentrations (0, 1, and 5 mM), and measured at three time points (0, 15, and 30 min), with a graphite anode. Viability is measured against EMT-6 cells using NADPH-flourescence assay and visual inspection following exclusion dye assay after 24 h treatment incubation. *: Student's t-test: 95% significant difference. **: Experimental data from Boudreau J. 2012. Electrochemical Generation of Reactive Toxicants and their application as chemotherapeutics. Thesis defense presentation. Pg. 22-23. University of Guelph.​

​

The toxicological principle that Figure 1 demonstrates is that: the cancer cells are not able to metabolize the prodrugs, this means that conventional molecules used in intratumor injection run a high risk of not working properly depending on tumor type even at extremely high local concentrations. Even if the concentration of prodrug is increased five-fold: there is no toxicity without electrolysis (Figure 1).

 

When you demonstrate that one of the longest and most widely used anti-cancer drugs: cyclophosphamide, is essentially nontoxic to cancer cells at millimolar concentrations (x0.001) after a 24 hour exposure, the results become a different story.

​​

The Publications Page has more light-bulb toxicity demonstrations like this, but that's the point: the EAC technology is not just one drug, it is more! 

​​

An ideal EAC molecule is:

• bioactivatable; and,

• a non-toxic prodrug; and,

• only activated by a CGP, like The Joey™; and,

• short-lived but stable enough to be financially valuable; and,

• able to be be stored in fluctuating environmental conditions for a long period of time; and,

• already has a known biological profile; and,

• already has regulatory approvals; and,

• already has a large manufacturing base.

​​​​These qualities make EAC development ideal for cancer treatments, antibiotics, rural markets, pesticides, harsh environments, explosives, and space travel.
 

Additionally: EAC opens the door to be able to use different molecules whose mechanisms of action are too non-specific, systemically toxic, and or for molecules whose reactivities are too short-lived to formulate oral or intravenous formulations.

By sourcing the drug activation mechanism of actual biological enzymes the EAC process and the patented CGP devices act as artificial enzyme themselves!